Dynastat
- Dynastat DCB
- parecoxibe
- Formas
- Pó e solvente para solução injetável; Pó para solução injetável
- Dosagem
- 40 mg
- Alternativas
- Desconhecidas
What is this? Dynastat is a pain-relief medicine given as an injection. It contains the active substance parecoxib.
What's happening? There is a shortage of Dynastat injections in the EU. Supplies are running low or unavailable.
Does this affect me? If you need this medicine for pain relief, you may be affected. Check with your doctor or pharmacist.
What should I do? Ask your pharmacist or doctor about other pain-relief options while supplies are low.
🤖 Este resumo em linguagem simples é gerado automaticamente a partir do comunicado oficial da agência, com recurso a IA. Destina-se apenas a fins informativos — não constitui aconselhamento médico. Para tomar decisões sobre a sua saúde, consulte sempre um farmacêutico ou médico e leia a fonte oficial vinculada abaixo.
📋 Da notificação oficial da agência
Atualizado há 1 semana- Última atualização
- 04/12/2025
- Primeira publicação
- 14/04/2025
- Medicamentos afetados
- Dynastat
- Pontos afetados
- 40 mg
- Resolução esperada
- January 2026 in Malta February 2026 in Greece March 2026 in Cyprus and France July 2026 in Bulgaria and Norway
- Status de escassez de suprimentos
- Ongoing
- Disponibilidade de alternativas
- Unknown
- Formas farmacêuticas afetadas
- Powder and solvent for solution for injectionPowder for solution for injection
- Nome internacional não proprietário (INN) ou nome comum
- parecoxib
Conteúdo da página
Informações sobre escassez
There is a shortage of Dynastat in some Members States of the European Economic Area (EEA).
Dynastat is a medicine used in adults for the short-term relief of pain after an operation. It is given by injection into a vein or muscle.
For further information on the use of the medicine, please refer to the medicine’s overview page.
The shortage is due to a reduction in the production capacity of Dynastat, following a temporary shutdown of one of the company’s production lines. The company is prioritising supply to markets where shortages are considered critical, with no country in the EEA currently experiencing critical shortages. Although the affected line has now resumed production, the company will need time to meet the current demand for Dynastat in the EEA.
The shortage currently affects seven EEA countries where the product is marketed: Cyprus, Greece, Malta, Bulgaria, France, Germany and Norway. The shortage in the Netherlands and Iceland is now resolved.
The shortage is expected to last until:
- January 2026 in Malta;
- February 2026 in Greece;
- March 2026 in Cyprus and France;
- July 2026 in Bulgaria and Norway.
Other EEA countries are at risk of shortage and the above information may change. For up-to-date information about the status of a medicine shortage in a particular Member State, consult the national shortage register or contact the national competent authority.
EMA’s Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) and EMA’s shortages working party (Medicines Shortages Single Point of Contact – SPOC - working party) are closely monitoring the supply situation and engaging with the marketing authorisation holder to mitigate the impact of the supply shortage.
In addition, the marketing authorisation holder is working to expedite and coordinate the distribution of Dynastat in a way that minimises the impact of shortages and is exploring options to increase its production.
- Before starting treatment, healthcare professionals should ensure that sufficient supplies of Dynastat are available.
- Doctors should consider other medicines for post-operative pain relief if Dynastat is not available in their country, taking into consideration local and national guidance.
- For additional information, consult your country’s shortage register or contact your national competent authority.
- Before starting treatment, your doctor will ensure that sufficient supplies of Dynastat are available.
- If Dynastat is not available in your country, there may be alternative medicines available for pain control which your doctor can prescribe.
- If you have any questions, speak to your doctor or pharmacist.
- For additional information, consult your country’s shortage register or contact your national competent authority.
Motivo da escassez
The shortage is due to a reduction in the production capacity of Dynastat, following a temporary shutdown of one of the company’s production lines. The company is prioritising supply to markets where shortages are considered critical, with no country in the EEA currently experiencing critical shortages. Although the affected line has now resumed production, the company will need time to meet the current demand for Dynastat in the EEA.
Estados-Membros afetados
The shortage currently affects seven EEA countries where the product is marketed: Cyprus, Greece, Malta, Bulgaria, France, Germany and Norway. The shortage in the Netherlands and Iceland is now resolved.
The shortage is expected to last until:
- January 2026 in Malta;
- February 2026 in Greece;
- March 2026 in Cyprus and France;
- July 2026 in Bulgaria and Norway.
Other EEA countries are at risk of shortage and the above information may change. For up-to-date information about the status of a medicine shortage in a particular Member State, consult the national shortage register or contact the national competent authority.
Monitorização de escassez
EMA’s Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) and EMA’s shortages working party (Medicines Shortages Single Point of Contact – SPOC - working party) are closely monitoring the supply situation and engaging with the marketing authorisation holder to mitigate the impact of the supply shortage.
In addition, the marketing authorisation holder is working to expedite and coordinate the distribution of Dynastat in a way that minimises the impact of shortages and is exploring options to increase its production.
Recomendações para profissionais de saúde
- Before starting treatment, healthcare professionals should ensure that sufficient supplies of Dynastat are available.
- Doctors should consider other medicines for post-operative pain relief if Dynastat is not available in their country, taking into consideration local and national guidance.
- For additional information, consult your country’s shortage register or contact your national competent authority.
Recomendações para doentes e cuidadores
- Before starting treatment, your doctor will ensure that sufficient supplies of Dynastat are available.
- If Dynastat is not available in your country, there may be alternative medicines available for pain control which your doctor can prescribe.
- If you have any questions, speak to your doctor or pharmacist.
- For additional information, consult your country’s shortage register or contact your national competent authority.
Principais informações
- Medicines affected
- Dynastat
- Supply shortage status
- Ongoing
- International non-proprietary name (INN) or common name
- parecoxib
- Pharmaceutical forms affected
- Powder and solvent for solution for injection
- Powder for solution for injection
- Strengths affected
- 40 mg
- Availability of alternatives
- Unknown
Datas importantes
- Expected resolution
- January 2026 in Malta
February 2026 in Greece
March 2026 in Cyprus and France
July 2026 in Bulgaria and Norway - First published
- Last updated
Informações relacionadas sobre saúde
🔬 Detalhes médicos/técnicos (para profissionais)
INN: parecoxib · Forms: Powder and solvent for solution for injection;Powder for solution for injection · Strengths: 40 mg · Alternatives: Unknown
Todas as informações desta página são provenientes do comunicado oficial da agência. Nós as traduzimos e resumimos; não adicionamos nem editamos factos.